Evidence map›Paper›PMID 39133717›Full record

ArticlePloS one2024

Recruiting transgender men in the Southeastern United States for genital microbiome research: Lessons learned.

Olivia T Van Gerwen, Z Alex Sherman, Emma Sophia Kay, Jay Wall, Joy Lewis, Isaac Eastlund, Keonte J Graves, Saralyn Richter, Angela Pontius, Kristal J Aaron and 7 more

Abstract read
In one paragraph

Article in PloS one, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Olivia T Van GerwenDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.ORCID 0000-0002-9362-6234
Z Alex ShermanDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Emma Sophia KaySchool of Nursing, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.ORCID 0000-0002-8425-9196
Jay WallMagic City Wellness Center, Birmingham, Alabama, United States of America.
Joy LewisDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Isaac EastlundDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Keonte J GravesDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Saralyn RichterDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Angela PontiusDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Kristal J AaronDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.ORCID 0000-0002-9285-7321
Krishmita SiwakotiDivision of Endocrinology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Ben RogersUniversity of Alabama at Birmingham Heersink School of Medicine, Birmingham, Alabama, United States of America.
Evelyn TohDepartment of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, Indiana, United States of America.
Jacob H ElnaggarDepartment of Microbiology, Immunology, and Parasitology, Louisiana Health Sciences Center New Orleans, New Orleans, Louisiana, United States of America.
Christopher M TaylorDepartment of Microbiology, Immunology, and Parasitology, Louisiana Health Sciences Center New Orleans, New Orleans, Louisiana, United States of America.ORCID 0000-0002-7983-5275
Nicholas J Van WagonerDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.
Christina A MuznyDivision of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama, United States of America.ORCID 0000-0002-4005-3858

Funding

CTSA K12 Program at the University of Alabama at BirminghamK12TR004769 · NCATS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Renee A. Heffron, Lucio Miele · 2024 to 2026
$4.8M
The Brown Initiative in HIV and AIDS Clinical Research for Minority CommunitiesR25MH083620 · NIMH · MIRIAM HOSPITAL · PI NUNN, AMY STEWART · 2008 to 2025
$3.7M
The Impact of Testosterone Use on the Vaginal Microbiota in Transgender Men, including Susceptibility to Bacterial VaginosisR21AI167754 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MUZNY, CHRISTINA A, TAYLOR, CHRISTOPHER MICHAEL · 2022 to 2023
$439k
NCATS NIH HHS K12 TR004769NIAID NIH HHS R21 AI167754NIMH NIH HHS R25 MH083620
6 · The paper itself

Abstract

backgroundTransgender men (TGM) are underrepresented in genital microbiome research. Our prospective study in Birmingham, AL investigated genital microbiota changes over time in TGM initiating testosterone, including the development of incident bacterial vaginosis (iBV). Here, we present lessons learned from recruitment challenges encountered during the conduct of this study.

methodsInclusion criteria were assigned female sex at birth, TGM or non-binary identity, age ≥18 years, interested in injectable testosterone but willing to wait 7 days after enrollment before starting, and engaged with a testosterone-prescribing provider. Exclusion criteria were recent antibiotic use, HIV/STI infection, current vaginal infection, pregnancy, or past 6 months testosterone use. Recruitment initiatives included community advertisements via flyers, social media posts, and referrals from local gender health clinics.

resultsBetween February 2022 and October 2023, 61 individuals contacted the study, 17 (27.9%) completed an in-person screening visit, and 10 (58.8%) of those screened were enrolled. The primary reasons for individuals failing study screening were having limited access to testosterone-prescribing providers, already being on testosterone, being unwilling to wait 7 days to initiate testosterone therapy, or desiring the use of topical testosterone. Engagement of non-White TGM was also minimal.

conclusionDespite robust study inquiry by TGM, screening and enrollment challenges were faced including engagement by TGM not yet in care and specific study eligibility criteria. Excitement among TGM for research representation should be leveraged in future work by engaging transgender community stakeholders at the inception of study development, particularly regarding feasibility of study inclusion and exclusion criteria, as well as recruitment of TGM of color. These results also highlight the need for more clinical resources for prescribing gender-affirming hormone therapy, especially in the Southeastern US.

Indexed as

MicrobiotaTransgender PersonsAdultFemaleHumansMaleMiddle AgedPatient SelectionProspective StudiesSoutheastern United StatesTestosteroneVaginosis, BacterialTestosterone

Identifiers

PMID39133717
PMCPMC11318884

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.